Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month target […]
StockNews.com began coverage on shares of Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) in a report published on Thursday. The brokerage issued a hold rating on the stock. KPTI has been the topic of a number of other research reports. Piper Sandler began coverage on Karyopharm Therapeutics in a research report on Thursday, January 19th. They […]
StockNews.com initiated coverage on shares of Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) in a research report released on Thursday morning. The brokerage issued a hold rating on the stock. Other research analysts have also recently issued research reports about the stock. Morgan Stanley decreased their target price on shares of Karyopharm Therapeutics from $7.00 to […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year target […]